FDA cancels the Core Drug Advisory Committee meeting, Biohaven (BHVN.US) surges more than 10% in pre-market trading.

According to the Intelligent Financial APP, the US Food and Drug Administration (FDA) canceled the advisory committee (AdCom) meeting planned for Biohaven's (BHVN.US) core drug troriluzole. The stock of the company surged significantly before the US stock market opened on Friday, up 12.3% as of the time of writing.